15.64 USD
+0.04 (+0.26%)
15.64 USD
0 (0%)
Taking everything into account, SGRY scores 3 out of 10 in our fundamental rating. SGRY was compared to 101 industry peers in the Health Care Providers & Services industry. SGRY has a medium profitability rating, but doesn't score so well on its financial health evaluation. SGRY has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
In the past year SGRY had a positive cash flow from operations.
SGRY had negative earnings in each of the past 5 years.
Each year in the past 5 years SGRY had a positive operating cash flow.
1.2 Ratios
SGRY has a Return On Assets (-2.16%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -9.94%, SGRY is in line with its industry, outperforming 44.55% of the companies in the same industry.
With a Return On Invested Capital value of 5.57%, SGRY perfoms like the industry average, outperforming 57.43% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for SGRY is below the industry average of 9.21%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROIC | 5.57% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
With an excellent Operating Margin value of 15.78%, SGRY belongs to the best of the industry, outperforming 94.06% of the companies in the same industry.
SGRY's Operating Margin has been stable in the last couple of years.
The Gross Margin of SGRY (26.57%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SGRY is destroying value.
Compared to 1 year ago, SGRY has more shares outstanding
Compared to 5 years ago, SGRY has more shares outstanding
Compared to 1 year ago, SGRY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.76, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.76, SGRY is doing worse than 75.25% of the companies in the same industry.
SGRY has a debt to FCF ratio of 18.37. This is a negative value and a sign of low solvency as SGRY would need 18.37 years to pay back of all of its debts.
SGRY's Debt to FCF ratio of 18.37 is in line compared to the rest of the industry. SGRY outperforms 40.59% of its industry peers.
SGRY has a Debt/Equity ratio of 2.00. This is a high value indicating a heavy dependency on external financing.
SGRY has a worse Debt to Equity ratio (2.00) than 73.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Altman-Z | 0.76 |
ROIC/WACC0.62
WACC8.95%
2.3 Liquidity
A Current Ratio of 1.88 indicates that SGRY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.88, SGRY is in the better half of the industry, outperforming 78.22% of the companies in the same industry.
SGRY has a Quick Ratio of 1.72. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
SGRY's Quick ratio of 1.72 is fine compared to the rest of the industry. SGRY outperforms 73.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
SGRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.14%.
The Revenue has been growing by 11.20% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
Based on estimates for the next years, SGRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.89% on average per year.
Based on estimates for the next years, SGRY will show a small growth in Revenue. The Revenue will grow by 7.88% on average per year.
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.05, which indicates a rather expensive current valuation of SGRY.
Compared to the rest of the industry, the Price/Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 70.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.92, SGRY is valued a bit cheaper.
A Price/Forward Earnings ratio of 20.86 indicates a rather expensive valuation of SGRY.
Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than 61.39% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.57. SGRY is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.05 | ||
| Fwd PE | 20.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 78.22% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, SGRY is valued cheaper than 85.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.43 | ||
| EV/EBITDA | 8.35 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
5. Dividend
5.1 Amount
No dividends for SGRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
15.64
+0.04 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners80.81%
Inst Owner Change0%
Ins Owners1.11%
Ins Owner Change-0.17%
Market Cap2.02B
Revenue(TTM)3.29B
Net Income(TTM)-171.90M
Analysts81.11
Price Target26.52 (69.57%)
Short Float %18.68%
Short Ratio7.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-23.03%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.06%
Min EPS beat(4)-24.34%
Max EPS beat(4)24.15%
EPS beat(8)5
Avg EPS beat(8)2.45%
EPS beat(12)9
Avg EPS beat(12)185.54%
EPS beat(16)10
Avg EPS beat(16)107.47%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.63%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)-0.71%
Revenue beat(16)5
Avg Revenue beat(16)-1.03%
PT rev (1m)-8.13%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-34.77%
EPS NY rev (1m)0%
EPS NY rev (3m)-25.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.05 | ||
| Fwd PE | 20.86 | ||
| P/S | 0.62 | ||
| P/FCF | 10.43 | ||
| P/OCF | 7.18 | ||
| P/B | 1.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.35 |
EPS(TTM)0.78
EY4.99%
EPS(NY)0.75
Fwd EY4.79%
FCF(TTM)1.5
FCFY9.59%
OCF(TTM)2.18
OCFY13.94%
SpS25.42
BVpS13.37
TBVpS-26.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.16% | ||
| ROE | -9.94% | ||
| ROCE | 7.05% | ||
| ROIC | 5.57% | ||
| ROICexc | 5.57% | ||
| ROICexgc | 18.41% | ||
| OM | 15.78% | ||
| PM (TTM) | N/A | ||
| GM | 26.57% | ||
| FCFM | 5.9% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2 | ||
| Debt/FCF | 18.37 | ||
| Debt/EBITDA | 5.17 | ||
| Cap/Depr | 58.56% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 42.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.72 | ||
| Altman-Z | 0.76 |
F-Score4
WACC8.95%
ROIC/WACC0.62
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-29.92%
EPS Next 2Y-10.69%
EPS Next 3Y0.93%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.14%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year6.88%
Revenue Next 2Y7.52%
Revenue Next 3Y7.62%
Revenue Next 5Y7.88%
EBIT growth 1Y15.88%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year41.53%
EBIT Next 3Y20.05%
EBIT Next 5YN/A
FCF growth 1Y32.24%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y18.25%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SGRY.
What is the valuation status for SGRY stock?
ChartMill assigns a valuation rating of 4 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
What is the financial health of SURGERY PARTNERS INC (SGRY) stock?
The financial health rating of SURGERY PARTNERS INC (SGRY) is 2 / 10.
What is the earnings growth outlook for SURGERY PARTNERS INC?
The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to decline by -29.92% in the next year.